Healthcare / BiotechnologyCanadian Sec
$0.75
+0.11 (+17.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-672656.00 · quality 31.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$61M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-78.0%
↓Gross Margin
N/A
•Debt/Equity
1.73
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+100.2%
FCF CAGR
—
FCF margin
-14.1%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.8M · net income $-1.6M · FCF $-672656.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.8M | $4.8M | $4.3M | $2.8M | $595398.00 |
| Net Income | $-1.6M | $-1.6M | $-1.3M | $-718094.00 | $-5.7M |
| EBITDA | $-587016.00 | $-587016.00 | $-456600.00 | $-414496.00 | $-5.5M |
| EPS | -0.03 | -0.03 | -0.02 | -0.01 | -0.12 |
| Gross Margin | — | — | — | 99.9% | -56.2% |
| Operating Margin | -28.2% | -28.2% | -24.5% | -25.6% | -966.9% |
| Net Margin | -32.7% | -32.7% | -31.0% | -25.4% | -965.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.73 | 1.73 | 1.34 | — | — |
| Current Ratio | 3.33 | 3.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-672656.00 | $-672656.00 | $-19801.00 | $-1.8M | $-2.6M |
| Returns | |||||
| ROE | -78.0% | -78.0% | -87.2% | -27.9% | -343.6% |
| Valuation | |||||
| P/B | 20.09 | 20.09 | 15.56 | 5.22 | 7.53 |
| Growth & Yield | |||||
| Revenue Growth | 12.0% | 12.0% | 51.1% | 374.3% | — |
| EPS Growth | -50.0% | -50.0% | -100.0% | 91.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+154.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.03
Residual
+154.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.